Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | Edinburgh Drug Discovery | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
Test |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
TB Drug Accelerator
View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Vanderbilt Enters Into Collaboration With BMS to Develop Drugs to treat Parkinsons DiseaseVanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Bristol-Myers Squibb Company have entered into a broad collaboration agreement to co-develop new drugs to treat Parkinsons Disease. Under the collaboration agreement VCNDD will identify... View all |
No EVENTS for listing |
No Job Posts |
